CD38
Showing 1 - 25 of 3,904
Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)
Not yet recruiting
- Non-hodgkin Lymphoma
- CD38-SADA:177Lu-DOTA Complex
- (no location specified)
Aug 15, 2023
Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Evan Syndrome
- Treatment
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023
Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Antiphospholipid Syndrome
- Thrombocytopenia
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023
Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)
Recruiting
- Acute Myeloid Leukemia
- CLL1 and CD38 dual-target CAR-T injection
-
Kunming, Yunnan, China920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023
Acquired Hemophilia Trial in Tianjin (Daratumumab)
Recruiting
- Acquired Hemophilia
-
Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023
Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)
Not yet recruiting
- Antibody-mediated Rejection
- Kidney Tranplant
-
Hangzhou, Zhejiang, China79# Qingchun Road
Jun 21, 2023
Advanced Solid Tumor Trial in New York (STI-6129)
Not yet recruiting
- Advanced Solid Tumor
- STI-6129
-
New York, New YorkColumbia University Medical Center
Jan 26, 2023
Light Chain (AL) Amyloidosis Trial (STI-6129)
Not yet recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
- (no location specified)
Jan 11, 2023
Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)
Recruiting
- Multiple Myeloma
- 89Zr-daratumumab PET/CT
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
Aug 1, 2022
Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)
Not yet recruiting
- Nephrotic Syndrome
- Rituximab Biosimilar ABP 798
- Daratumumab
-
Genova, ItalyIRCCS G. Gaslini
Jan 19, 2023
Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
-
Duarte, California
- +21 more
Jan 17, 2023
AML Trial in Hangzhou (CD38 CAR T-cells)
Recruiting
- AML
- CD38 CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)
Recruiting
- Multiple Myeloma
- STI-1492
-
Orange, California
- +2 more
Jan 12, 2023
Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- STI-6129
-
Beijing, Beijing, China
- +3 more
Jan 9, 2023
Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)
Recruiting
- Acute Myeloid Leukemia
- CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Light Chain (AL) Amyloidosis Trial in New York (STI-6129)
Recruiting
- Light Chain (AL) Amyloidosis
- STI-6129
-
Duarte, California
- +3 more
Jan 12, 2023
Multiple Myeloma Trial in Canton (STI-6129)
Recruiting
- Multiple Myeloma
- STI-6129
-
Canton, OhioGabrail Cancer Center
Jun 29, 2022
AL Amyloidosis Trial in Scottsdale, Jacksonville, Rochester (procedure, biological, other)
Not yet recruiting
- AL Amyloidosis
- Bone Marrow Biopsy
- +4 more
-
Scottsdale, Arizona
- +2 more
Jun 2, 2023
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,
Active, not recruiting
- Bladder Urothelial Carcinoma
- +4 more
- Biopsy
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Recruiting
- Plasma Cell Myeloma
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 27, 2022